Search Results
Your search for ,WHo matches 20933 pages
Showing 3051 - 3100Early Cessation of Neoadjuvant Chemotherapy May Lead to Worse Outcomes in Patients With Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer who receive fewer than three cycles of chemotherapy prior to cystectomy may have an increased risk of cancer recurrence and worse survival outcomes, according to the findings of a retrospective study presented by Chakraborty et al at the 2023 ASCO Annual ...
Zanidatamab Shows Activity in Refractory HER2-Amplified Biliary Tract Cancer
The HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer, according to research presented by Shubham Pant, MD, and colleagues at the 2023 ASCO Annual Meeting (Abstract 4008). The results were also...
Addition of Olaparib and Durvalumab to Standard of Care May Prolong Progression-Free Survival in Patients With Advanced Ovarian Cancer
Patients with newly diagnosed advanced ovarian cancer without a BRCA mutation who received durvalumab and olaparib in addition to the standard of care had improved progression-free survival compared with those who received the standard of care alone, according to the interim analysis of DUO-O, an...
Adding Ribociclib to Endocrine Therapy May Reduce Recurrence Risk in Patients With Hormone Receptor–Positive, HER2-Negative Early-Stage Breast Cancer
Adding the CDK4/6 inhibitor ribociclib to endocrine therapy resulted in a significant improvement in invasive disease–free survival for patients with hormone receptor–positive, HER2-negative early-stage breast cancer. Findings from the phase III NATALEE trial were presented by Dennis J. Slamon, MD, ...
Simple Hysterectomy May Be a Safe Option for Patients With Early-Stage, Low-Risk Cervical Cancer
Simple hysterectomy with pelvic lymph node dissection may be a safe treatment option for patients with early-stage, low-risk cervical cancer and may help improve quality of life, according to results from the large, international phase III SHAPE clinical trial. The research was presented by Plante...
Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection
Marie Plante, MD, of Canada’s Université Laval and the CHUQ Hotel Dieu de Québec, discusses phase III results from a study that compared radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer. The...
Extended Lymphadenectomy May Not Benefit Patients With Clinically Localized Muscle-Invasive Bladder Cancer
Extended lymphadenectomy in patients undergoing radical cystectomy for clinically localized muscle-invasive bladder cancer was not associated with improved disease-free survival or overall survival and may increase the risk of adverse events and postsurgical mortality, according to new findings...
Study Finds Wide Variations in Intratumoral Microbiome of Patients With Early- vs Late-Onset Colorectal Cancer
Researchers have found that the bacteria, fungi, and viruses within the tumors of patients with colorectal cancer varied significantly depending on whether they were diagnosed with early-onset or late-onset disease, according to new findings presented by Weinberg et al at the 2023 ASCO Annual...
ATOM Coalition Seeks to Ensure Equitable Cancer Care in Low- and Middle-Income Countries
A new global health initiative, the Access to Oncology Medicines (ATOM) Coalition, may be capable of reducing the burden of suffering and death from cancer in low- and middle-income countries by improving patient access to essential cancer medicine. Gilberto Lopes, MD, FASCO, MBA, will highlight...
FDA Approves Olaparib Plus Abiraterone and Prednisone or Prednisolone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 31, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in combination with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an...
Finding Early Female Role Models Helped Shape a Notable Career in Oncology
Elizabeth M. Jaffee, MD, Deputy Director of The Sidney Kimmel Comprehensive Cancer Center, Baltimore, was born in Brooklyn, New York, in a place and time she found exhilarating during her early years. “We didn’t have a lot of money—actually, we were poor. But I had a lot of freedom walking around...
Daughter of Immigrants Who Fled the Pogroms, She Followed a Love of Science Into a Noted Career in Cancer Pathology
In the era of genomics and precision medicine, the role of pathology in diagnosis and cancer management is rapidly evolving. For the past 50 years, from her office at the Center for Cancer Research, National Cancer Institute (NCI), pathologist Elaine S. Jaffe, MD, has been at the forefront of that...
SGLT2 Inhibitors and Cardiovascular Outcomes in Older, Anthracycline-Treated Patients With Cancer
In a population-based cohort study reported in JACC: CardioOncology, Abdel-Qadir et al found that receipt of sodium glucose cotransporter-2 (SGLT2) inhibitors was associated with a reduced risk of hospitalization for heart failure—but not risk for heart failure—among patients aged ≥ 65 years with...
Diffusing Alpha-Emitter Radiation Therapy for Recurrent or Unresectable Skin Cancers
In a small study reported in JAMA Network Open, D’Andrea et al found that diffusing alpha-emitter radiation therapy—a novel solid tumor management strategy using alpha-particle interstitial brachytherapy—appeared to be safe and showed activity in patients with recurrent or unresectable skin...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award recipients at the...
An Oncology Leader Whose Immigrant Parents Taught Him by Example About Life and Service to Humanity
According to Sunil R. Hingorani, MD, PhD, his parents figured heavily on who he became as a person and on his career choices, which ultimately led to his current position as Director of the Pancreatic Cancer Center of Excellence at the University of Nebraska College of Medicine, Omaha. “My father...
Involvement in SWOG and JCO Leads to a Fulfilling Career as a Leader in Oncology
Jonathan W. Friedberg, MD, MMSc, Director of the James P. Wilmot Cancer Institute, grew up in a suburb of Milwaukee. While his school friends were attending camp, he spent his summers working on the family farm. “Perhaps the hardest work I’ve ever done was haying on a hot, humid night in July,...
An Oncologist From Guam Devotes His Career to the Care of Pelvic Cancers and the Sexual Health of All Cancer Survivors
Don S. Dizon, MD, FACP, FASCO, Director of Pelvic Malignancies Program at Lifespan Cancer Institute and Director of Medical Oncology at Rhode Island Hospital was born and reared in Guam. He also is Professor of Medicine and Professor of Surgery at Brown University, Providence, Rhode Island. “I am...
The Second-Generation Son of Greek Immigrants, the First to Go to College, Becomes a Leader in Sarcoma Research and Treatment
George D. Demetri, MD, FASCO, Director of the Sarcoma Center at Dana-Farber Cancer Institute, and Professor of Medicine and Co-Director of the Ludwig Center at Harvard, was born in Hyde Park, a town along the Hudson River in New York. When Dr. Demetri was growing up there, it was known for three...
Patients Who Practice Qigong May Be Able to Improve Their Cancer-Related Fatigue
Researchers have found that patients with cancer-related fatigue who practiced qigong may have demonstrated clinically significant improvements in their fatigue burden after 10 weeks, according to a new study published by Zimmerman et al in Integrative Cancer Therapies. The findings revealed that...
HER3-Targeting Antibody-Drug Conjugates Show Encouraging Results in Breast Cancer Subtypes
Early-phase data from the SOLTI TOT-HER3 and ICARUS-BREAST01 trials suggest that the novel HER3-directed antibody-drug conjugate patritumab deruxtecan may have beneficial activity in patients with hormone receptor–positive/HER2-negative and triple-negative breast cancer subtypes, according to...
Mourned and Missed
The respected members of the oncology community listed here are among some of those who passed away in 2022–2023. The ASCO Post remembers them, their lives, and their contributions to cancer research and treatment. Robert J. Gillies, PhD Moffitt Cancer Center and the global research community lost ...
A Leader in Oncology From Humble Beginnings Never Forgets Life Lessons Learned Along the Way
In December 2019, Robert A. Winn, MD, became the second Black physician to lead a National Cancer Institute (NCI)-designated comprehensive cancer center when he took the helm of the Virginia Commonwealth University (VCU) Massey Cancer Center. Dr. Winn’s basic science research, which has been...
A Love of Immunology Leads to a Notable Career in Dermatology, With a Focus on Melanoma Research and Treatment
Caroline Robert, MD, PhD, Head of the Dermatology Unit at Gustave Roussy and Co-Director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, was born and reared in Paris. “I didn’t have a vocation for medicine when I was a kid; I wanted to be an archeologist. I’m not from a medical...
Inspired by an Uncle Who Was a Compassionate Family Doctor, This Nonagenarian Continues a Renowned Career in Hematology
Today is the era of the multidisciplinary oncology care approach, cancer staging facilitates precision in documenting disease extent, all of which improved the quality of patient care. However, in the United States, the Rai staging system is still the most commonly used clinical staging system for...
From a Small Town in North Carolina, a Young Girl Finds Her Calling in Battling Inequity in Cancer Care
Manali Patel, MD, MPH, Associate Professor of Medicine (Oncology) at Stanford University, grew up in Shelby, a small town in the textile and farming community of Western North Carolina, among mill workers and other blue-collar laborers. The daughter of Indian immigrants, Dr. Patel’s early life was...
A Free-Spirited Childhood on a Dairy Farm, Where Books and Science Experiments Were Encouraged
Susan K. Parsons, MD, MRP, Professor of Medicine and Pediatrics at Tufts University School of Medicine and Founding Director of the Reid R. Sacco Adolescent and Young Adult Program for Cancer and Hereditary Blood Disorders at Tufts Medical Center, grew up on a working dairy farm in Sharon Springs,...
FDA Approves Flotufolastat Fluorine-18 Injection, First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer
On May 30, the U.S. Food and Drug Administration (FDA) approved the optimized, high-affinity radiohybrid prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) imaging agent flotufolastat fluorine-18 (Posluma). Flotufolastat F-18 is indicated for PET imaging of...
Incidence of Colorectal, Lung, and Breast Cancers May Be Rising Due to COVID-19–Related Screening Delays
Delays in cancer screenings during the COVID-19 pandemic may have resulted in lower reported incidences of colorectal, lung, and breast cancers, reflecting potentially high rates of undiagnosed cancer and later-stage diagnoses, according to a new study published by Romatoski et al in the Journal of ...
New Bladder Cancer Classification May Predict Response to BCG Immunotherapy in Patients With Non–Muscle-Invasive Bladder Cancer
Researchers have developed a new strategy to identify which patients with non–muscle-invasive bladder cancer may be most likely to resist first-line treatment with Bacillus Calmette-Guérin (BCG) immunotherapy, according to a new study published by Jong et al in Science Translational Medicine. The...
MGMT Promoter Methylation and Survival Outcomes in Low-Grade and Anaplastic Gliomas After Alkylating Chemotherapy
In a study reported in JAMA Oncology, Kinslow et al found that MGMT promoter methylation (mMGMT) was associated with improved survival outcomes in patients receiving alkylating chemotherapy for low-grade and anaplastic gliomas. Study Details The study involved 411 patients with grade II or III...
Minimally Invasive Distal Pancreatectomy in Patients With Resectable Pancreatic Cancer
Results from the international, randomized DIPLOMA trial (ClinicalTrials.gov identifier NCT04483726) comparing minimally invasive distal pancreatectomy (MIDP) with open distal pancreatectomy (ODP) in patients with pancreatic ductal adenocarcinoma showed that the rate of radical resection following...
Using a Health Systems Strengthening Approach in the United States–Mexico Border Region Improved Survival Rates for Children With ALL
The implementation of a collaborative program between North American and Mexican medical institutions to achieve sustainable, high-quality care at a public hospital in the United States–Mexico border region for children with acute lymphoblastic leukemia (ALL) and improve outcomes has resulted in...
Medicaid Expansion Associated With a Reduction in Mortality for Black Patients With Gastrointestinal Cancers
Studies showed that racial minorities experience disparities in access to cancer treatment and survival. In an effort to improve access to care for disadvantaged populations, the Affordable Care Act provided funding to states to expand Medicaid eligibility criteria and provide coverage to...
Luspatercept Improves Reliance on Blood Transfusions for Patients With Lower-Risk MDS
Patients with lower-risk myelodysplastic syndromes (MDS) who received luspatercept to treat anemia instead of erythropoiesis-stimulating agents (ESAs)—the current standard of care—needed fewer blood transfusions and clinic visits. These findings from the phase III COMMANDS trial were presented by...
Adding Pembrolizumab to Chemotherapy May Improve Survival in Patients With Advanced Cervical Cancer
Adding the PD-1 inhibitor pembrolizumab to chemotherapy, with or without bevacizumab, improved overall survival and progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer, regardless of whether the cancer expressed PD-L1. These findings from the KEYNOTE-826...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award...
Making the Art of Oncology and Cancer Care Central to Her Presidential Term
Lynn M. Schuchter, MD, FASCO, has said that volunteering and working with ASCO over many years has been the highlight of her career. She served on the ASCO Board of Directors from 2009 to 2012 and on several ASCO committees, including terms as Chair of the Annual Meeting Scientific Program...
I Was Unprepared for a Diagnosis of Mantle Cell Lymphoma
The irony is not missed on me. In August 2022, 2 months before I was to start my tenure as President of the Union for International Cancer Control (UICC), I was diagnosed with mantle cell lymphoma. My entire career over the past 30 years has been in the pursuit of improving global cancer control...
Tumor Genomic Profile and Risk for Arterial Thromboembolism in Patients With Solid Cancer
In a single-institution study reported in JACC: CardioOncology, Stephanie Feldman, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that somatic KRAS and STK11 alterations were associated with increased risk of arterial thromboembolism in patients with solid tumors,...
Mount Sinai Achieves Highest Rating From Society of Thoracic Surgeons for Esophagectomy Program
The Mount Sinai Health System’s esophagectomy program has received a three-star (excellent performance) overall composite score from the Society of Thoracic Surgeons (STS). According to STS, 13 institutions in the United States and Canada hold the three-star rating, which denotes the highest...
Northwell Launches Cancer Care Direct, Pairing Nurse Navigators With Patients Through Spectrum of Care
Knowing the health-care system is complex and often creates anxiety for patients newly diagnosed with cancer, the Northwell Health Cancer Institute has launched Cancer Care Direct, a comprehensive program to connect patients with clinical registered nurse navigators who can provide expert guidance...
Surviving, but Not Always Thriving, After Cancer
As discussed in Part I of this special feature on cancer survivorship, there are now more than 18 million cancer survivors in the United States, and that number is expected to grow to 26 million by 2040.1 However, most of those survivors—at least two-thirds—either cured or in remission or living...
ASCO CEO Clifford A. Hudis, MD, FASCO, FACP, Discusses How the Cancer Care Community Will Meet the Daunting Challenges Ahead
With this issue of The ASCO Post, we introduce a new feature, View From the Top: The Future of Cancer Care Delivery, which will explore how leaders in oncology are developing strategies to ensure continued innovative oncology care in an ever-changing health-care environment. In this inaugural...
Surviving, but Not Always Thriving, After Cancer
The improvement in cancer survival rates since President Richard M. Nixon signed the National Cancer Act of 1971 into law is staggering. The legislation further committed the United States to greater investments in cancer-focused research to drive down the rates of cancer diagnoses, boost patient...
American College of Surgeons Evaluates the Impact of COVID-19 Pandemic on National Cancer Database Reporting
New research from the American College of Surgeons (ACS) outlines significant ways that the COVID-19 pandemic destabilized usual patterns of cancer care, as reported in the National Cancer Database (NCDB). The NCDB is one of the largest cancer registries in the world and is used by thousands of...
Highlighting Progress in Myeloma Treatment: POLLUX Trial Final Overall Survival Results With Daratumumab-Based Therapy
The updated results of the POLLUX trial, reported in the Journal of Clinical Oncology by Dimopoulos and colleagues and in this issue of The ASCO Post, showed significantly improved overall survival with daratumumab plus lenalidomide/dexamethasone (DRd) vs Rd in patients with previously treated...
New Roles at St. Louis Siteman Cancer Center
Daniel C. Link, MD, has been named Deputy Director of Siteman Cancer Center (SCC), based at Barnes-Jewish Hospital and Washington University School of Medicine, in St. Louis. In addition, Dr. Link, who also is the Alan A. and Edith L. Wolff Distinguished Professor of Medicine, is Chief of the...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Circulating Tumor DNA Identified Prior to and During Treatment Is Associated With Poorer Outcomes in Primary CNS Lymphoma
In a collaborative study from the University of Freiburg and Stanford University reported in the Journal of Clinical Oncology, Jurik A. Mutter, BSc, of the Faculty of Medicine, University of Freiburg, and colleagues found that circulating tumor DNA (ctDNA) identified prior to and during treatment...
